Somatostatin and Dopamine Receptor Profile of Gastroenteropancreatic Neuroendocrine Tumors: an Immunohistochemical Study

Overview

Journal Endocr Pathol

Specialties Endocrinology
Pathology

Date 2011 Feb 3

PMID 21287294

Citations 12

Authors

Evanthia Diakatou

Gregory Kaltsas

Michail Tzivras

George Kanakis

Eugenia Papaliodi

George Kontogeorgos

Affiliations

Soon will be listed here.

Abstract

Somatostatin and its synthetic analogs act through five specific somatostatin receptors (sstr1-5), found on the cell membrane of various tumors, including endocrine ones. Dopamine--a known neurotransmitter--acts through five membranous dopamine receptors (D1R-D5R) which have recently been found to be expressed in endocrine tumors. We evaluated the immunohistochemical expression of the sstrs and D2R in a large series of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). A total of 22 (28.94%) well-differentiated NETs (WDNETs), 6 (7.89%) WDNETs of uncertain biology, 26 (34.21%) well-differentiated neuroendocrine carcinomas, and 22 (28.94%) poorly differentiated neuroendocrine carcinomas were studied. Overall, 76.31% of the tumors were positive for different types of sstrs with variable intensity of the membranous staining whereas 36.95% were positive for D2R alone. The sstr2A was the most frequently expressed, followed by sstr2B, sstr1, and sstr5. Co-expression of sstrs and D2R was seen in 88.23% of positive tumors. The high rates of sstr2A and sstr2B and in a lower extent of sstr5 expression are of great importance for more accurate imaging, staging and targeted therapy of the disease. The co-expression of sstrs and D2R in a significant number of the studied cases offers a potential therapeutic alternative for GEP-NETs.

Citing Articles

The Role of Receptor-Ligand Interaction in Somatostatin Signaling Pathways: Implications for Neuroendocrine Tumors.

Milewska-Kranc A, Cwikla J, Kolasinska-Cwikla A Cancers (Basel). 2024; 16(1).

PMID: 38201544 PMC: 10778465. DOI: 10.3390/cancers16010116.

Reassessment of somatostatin receptor SST4 expression in bronchopulmonary and gastroenteropancreatic neuroendocrine neoplasms using the novel rabbit monoclonal anti-human SST4 antibody 7H49L61.

Ehms B, Kaemmerer D, Sanger J, Schulz S, Lupp A Sci Rep. 2022; 12(1):14722.

PMID: 36042228 PMC: 9428033. DOI: 10.1038/s41598-022-19014-w.

The dopaminergic control of Cushing's syndrome.

Pivonello R, Pivonello C, Simeoli C, De Martino M, Colao A J Endocrinol Invest. 2022; 45(7):1297-1315.

PMID: 35460460 PMC: 9184412. DOI: 10.1007/s40618-021-01661-x.

Role of Somatostatin Signalling in Neuroendocrine Tumours.

Rogoza O, Megnis K, Kudrjavceva M, Gerina-Berzina A, Rovite V Int J Mol Sci. 2022; 23(3).

PMID: 35163374 PMC: 8836266. DOI: 10.3390/ijms23031447.

Somatostatin-Dopamine Chimeric Molecules in Neuroendocrine Neoplasms.

Cantone M, Dicitore A, Vitale G J Clin Med. 2021; 10(3).

PMID: 33535394 PMC: 7867079. DOI: 10.3390/jcm10030501.

References

Volante M, Brizzi M, Faggiano A, La Rosa S, Rapa I, Ferrero A . Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol. 2007; 20(11):1172-82. DOI: 10.1038/modpathol.3800954. View

Oda Y, Tanaka Y, Naruse T, Sasanabe R, Tsubamoto M, Funahashi H . Expression of somatostatin receptor and effects of somatostatin analog on pancreatic endocrine tumors. Surg Today. 2002; 32(8):690-4. DOI: 10.1007/s005950200128. View

Kloppel G, Rindi G, Anlauf M, Perren A, Komminoth P . Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors. Virchows Arch. 2007; 451 Suppl 1:S9-27. DOI: 10.1007/s00428-007-0461-0. View

Lemmer K, Ahnert-Hilger G, Hopfner M, Hoegerle S, Faiss S, Grabowski P . Expression of dopamine receptors and transporter in neuroendocrine gastrointestinal tumor cells. Life Sci. 2002; 71(6):667-78. DOI: 10.1016/s0024-3205(02)01703-4. View

Weckbecker G, Briner U, Lewis I, Bruns C . SOM230: a new somatostatin peptidomimetic with potent inhibitory effects on the growth hormone/insulin-like growth factor-I axis in rats, primates, and dogs. Endocrinology. 2002; 143(10):4123-30. DOI: 10.1210/en.2002-220219. View

Rocheville M, Lange D, Kumar U, Patel S, Patel R, Patel Y . Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science. 2001; 288(5463):154-7. DOI: 10.1126/science.288.5463.154. View

Lamberts S, Krenning E, Reubi J . The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991; 12(4):450-82. DOI: 10.1210/edrv-12-4-450. View

Hofland L, Lamberts S . The pathophysiological consequences of somatostatin receptor internalization and resistance. Endocr Rev. 2003; 24(1):28-47. DOI: 10.1210/er.2000-0001. View

Reubi J, Schaer J, Waser B, Mengod G . Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res. 1994; 54(13):3455-9. View

10.

Kwekkeboom D, Kam B, Van Essen M, Teunissen J, van Eijck C, Valkema R . Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors. Endocr Relat Cancer. 2009; 17(1):R53-73. DOI: 10.1677/ERC-09-0078. View

11.

Corleto V, Scopinaro F, Angeletti S, Materia A, Basso N, Polettini E . Somatostatin receptor localization of pancreatic endocrine tumors. World J Surg. 1996; 20(2):241-4. DOI: 10.1007/s002689900038. View

12.

Schulz S, Schmitt J, Wiborny D, Schmidt H, Olbricht S, Weise W . Immunocytochemical detection of somatostatin receptors sst1, sst2A, sst2B, and sst3 in paraffin-embedded breast cancer tissue using subtype-specific antibodies. Clin Cancer Res. 1998; 4(9):2047-52. View

13.

Thodou E, Kontogeorgos G, Theodossiou D, Pateraki M . Mapping of somatostatin receptor types in GH or/and PRL producing pituitary adenomas. J Clin Pathol. 2006; 59(3):274-9. PMC: 1860351. DOI: 10.1136/jcp.2005.026914. View

14.

Papotti M, Croce S, Bello M, Bongiovanni M, Allia E, Schindler M . Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch. 2002; 439(6):787-97. DOI: 10.1007/s004280100494. View

15.

Papotti M, Kumar U, Volante M, Pecchioni C, Patel Y . Immunohistochemical detection of somatostatin receptor types 1-5 in medullary carcinoma of the thyroid. Clin Endocrinol (Oxf). 2001; 54(5):641-9. DOI: 10.1046/j.1365-2265.2001.01175.x. View

16.

Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M . Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol. 2000; 9(1):47-57. DOI: 10.1097/00019606-200003000-00008. View

17.

Patel Y . Somatostatin and its receptor family. Front Neuroendocrinol. 1999; 20(3):157-98. DOI: 10.1006/frne.1999.0183. View

18.

OToole D, Saveanu A, Couvelard A, Gunz G, Enjalbert A, Jaquet P . The analysis of quantitative expression of somatostatin and dopamine receptors in gastro-entero-pancreatic tumours opens new therapeutic strategies. Eur J Endocrinol. 2006; 155(6):849-57. DOI: 10.1530/eje.1.02307. View

19.

Florio T, Barbieri F, Spaziante R, Zona G, Hofland L, Van Koetsveld P . Efficacy of a dopamine-somatostatin chimeric molecule, BIM-23A760, in the control of cell growth from primary cultures of human non-functioning pituitary adenomas: a multi-center study. Endocr Relat Cancer. 2008; 15(2):583-96. DOI: 10.1677/ERC-07-0271. View

20.

Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder W . TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch. 2006; 449(4):395-401. PMC: 1888719. DOI: 10.1007/s00428-006-0250-1. View